Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition

INTRODUCTION: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have been successful in treating advanced malignancies; however, they also cause immune-related adverse events (irAE). Given that some irAE are clinically similar to traditional autoimmune diseases, autoantibodies h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Nilasha, Postow, Michael, Zhu, Chengsong, Jannat-Khah, Deanna, Li, Quan-Zhen, Vitone, Greg, Chan, Karmela K, Bass, Anne R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804686/
https://www.ncbi.nlm.nih.gov/pubmed/35091456
http://dx.doi.org/10.1136/jitc-2021-004008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804686/
https://www.ncbi.nlm.nih.gov/pubmed/35091456
http://dx.doi.org/10.1136/jitc-2021-004008

Ejemplares similares